Cardiomyocytes contain secretory granules in which chromogranins and several types of natriuretic peptides and growth factors are stored in addition to high Ca2+ concentrations. Yet the expression and serum levels of chromogranins and natriuretic peptides have been closely correlated with pathological cardiac hypertrophy and heart failure. Moreover, in distinction from the physiological cardiac hypertrophy that appears not to involve inositol 1,4,5-trisphosphate (IP3) production as the primary signaling step, accumulating evidence underscores the central role of IP3-induced intracellular Ca2+ releases in cardiomyocytes in the development of pathological cardiac hypertrophy. Consistent with this observation, chronic treatment of cardiomyocytes with G-protein coupled receptor agonists endothelin-1, angiotensin II, or phenylephrine, agents that are known to produce intracellular IP3, leads to cardiomyopathy and heart failure. In particular, the IP3-induced Ca2+ release inside the nucleus has been suggested to initiate a series of nuclear activities, including 1) Ca2+-calmodulin (CaM) mediated protein kinase II (CaMKII) activation, 2) activation of transcription factors such as myocyte enhancer factor-2 (MEF-2) and nuclear factor κB (NF-κB), and 3) increased production of chromogranins, natriuretic peptides, and growth factors, which eventually lead to pathological hypertrophy. Although secretory granules function as the major IP3-sensitive intracellular Ca2+ store and the IP3-mediated Ca2+ release from secretory granules in cardiomyocytes contributes to secretion of chromogranins and natriuretic peptides, the direct cause of pathological hypertrophy appears to be due to the IP3-induced Ca2+ release from the small nucleoplasmic IP3-sensitive Ca2+ store vesicles, thereby initiating the Ca2+-activated nuclear activities that lead to formation of more secretory granules, pathologic enlargement of cardiomyocytes, and heart failure.
Keywords: Chromogranins, secretogranins, IP3R/Ca2+ channels, cardiomyocytes, secretory granules, Ca2+, cardiomyopathy, cardiac hypertrophy, pathologic.
Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure
Current Pharmaceutical Design Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Editorial (Thematic Issue: Mitochondrial and Metabolism: Novel Targets for Heart Failure)
Current Pharmaceutical Design Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Anti-Inflammatory and Anti-Apoptotic Effects of Levosimendan in Decompensated Heart Failure: A Novel Mechanism of Drug-Induced Improvement in Contractile Performance of the Failing Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Management of Blood Pressure and Heart Rate in Acute Decompensated Heart Failure with Volume Overload
Current Pharmaceutical Design Cardiac Mitochondrial Alterations Observed in Hyperglycaemic Rats - What Can We Learn From Cell Biology?
Current Diabetes Reviews Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders